Monopar Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MNPR Nasdaq 2836 www.monopartx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Monopar Therapeutics Inc.

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 - Jun 1st, 2026 5:00 am
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - May 19th, 2026 3:33 pm
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - May 14th, 2026 12:00 pm
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans - May 3rd, 2026 7:26 am
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - Apr 19th, 2026 5:00 pm
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - Mar 27th, 2026 11:00 am
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer - Mar 2nd, 2026 6:00 am
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them. - Feb 11th, 2026 6:06 am
Broadcom Stock Sees Improved Relative Strength Rating - Feb 9th, 2026 11:21 am
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Dec 22nd, 2025 8:11 am
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? - Nov 22nd, 2025 5:47 am
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments - Nov 13th, 2025 6:00 am
Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls - Nov 10th, 2025 7:39 am
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 - Nov 9th, 2025 7:00 am
Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect? - Oct 21st, 2025 7:55 am
How the Narrative Around AstraZeneca Is Shifting Amid New Risks and Pipeline Developments - Oct 18th, 2025 12:07 pm
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy - Oct 16th, 2025 2:33 pm
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 - Oct 15th, 2025 6:00 am
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Sep 23rd, 2025 9:08 pm
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients - Sep 23rd, 2025 9:07 pm